New Mechanistic Study Proposes Multi-Compound Nutraceutical Strategy to Support Glucose Homeostasis in Type 2 Diabetes

Independent researcher presents evidence-based model targeting AMPK, PI3K/Akt, GLUT4, inflammation, and β-cell preservation

United States - February 2025 - Independent biotechnology and psychology researcher Jimmy Alexis has released a new scientific analysis proposing a multi-compound nutraceutical approach designed to support glucose homeostasis in individuals with Type 2 Diabetes Mellitus (T2DM). The research, now published as a scientific preprint, explores how botanical bioactive compounds may synergistically target key metabolic pathways involved in insulin resistance and β-cell decline.

T2DM affects over 537 million adults globally, and despite advances in pharmacological treatments, many patients continue to struggle with insulin resistance, chronic inflammation, oxidative stress, and progressive β-cell dysfunction. Alexis' new manuscript evaluates how a strategically formulated blend of plant-derived extracts may complement existing treatments through a multi-target biochemical strategy.

The study outlines mechanistic evidence demonstrating how select botanical compounds influence:

AMPK activation, enhancing insulin-independent glucose uptake

PI3K/Akt pathway signaling, improving insulin sensitivity

GLUT4 translocation, increasing peripheral glucose disposal

Inflammatory cytokine suppression, reducing IL-6, TNF-α, and NF-κB activity

β-cell preservation, mitigating oxidative stress and apoptosis

According to the analysis, combining compounds that affect these pathways could provide broader metabolic support than single-ingredient supplements or monotherapeutic agents.

"My goal is to explore scientific strategies that support metabolic balance by acting on multiple biochemical systems simultaneously," said researcher Jimmy Alexis.
"This work does not claim a cure, but it provides a scientifically grounded framework for developing next-generation nutraceuticals that complement lifestyle and medical interventions."

The manuscript also presents a proposed research roadmap including:

In vitro testing in skeletal muscle, hepatic, and pancreatic β-cell lines

Preclinical animal trials using high-fat-diet induced diabetic mice

A pilot human study evaluating HbA1c, fasting glucose, HOMA-IR, inflammatory markers, and C-peptide

This blueprint establishes a path for transitioning the theoretical formulation into validated scientific testing.

The full preprint is available on Zenodo and includes detailed mechanistic discussions, scientific rationale, proposed methodology, and references to current metabolic research.

About the Researcher

Jimmy Alexis is a biotechnology and psychology researcher originally from Haiti, raised in the Dominican Republic, and currently based in the United States. His research interests include Type 2 Diabetes, Alzheimer's disease, cancer biology, epidemiology, and the molecular mechanisms underlying chronic diseases. He is committed to developing accessible scientific insights that bridge biotechnology, psychology, and public health.

Access the Full Preprint

DOI: 10.5281/ZENODO.17705629
Zenodo Link: https://zenodo.org/records/17705629

Media Contact

Jimmy Alexis
Independent Researcher - Biotechnology & Psychology Student
ORCID: 0009-0008-2078-5200

Jimmy Alexis Research Initiative
239 4TH AVE
STE 1401
PITTSBURGH, PA 15222-1715

Contact Person: Jimmy Alexis
Email: jalexis3@student.umgc.edu
Phone: 2394456943
ORCID: 0009-0008-2078-5200
linkedin: https://linkedin.com/in/jimmyalexis
Country: United States

Jimmy Alexis Research Initiative is an independent scientific research entity focused on biotechnology, psychology, metabolic health, and chronic disease mechanisms. The initiative conducts conceptual, mechanistic, and exploratory research in areas including Type 2 Diabetes, Alzheimer's disease, cancer biology, inflammatory pathways, and nutraceutical development.

The enterprise emphasizes accessible scientific innovation, evidence-based analysis, and the integration of biotechnology with psychological and public-health perspectives. Research papers, technical analyses, and scientific models developed through the initiative are published openly on peer-reviewed and preprint platforms such as Zenodo, Preprints.org, and ORCID.

The initiative operates independently without institutional funding, focusing on early-stage scientific concepts that can guide future laboratory, preclinical, and clinical development. Its mission is to contribute meaningful knowledge to the scientific community, promote open-access science, and support innovations in disease treatment pathways.

This release was published on openPR.